UPDATE: Credit Suisse Initiates Arena Pharmaceuticals at Underperform on Belviq Expectations
Credit Suisse initiated its Arena Pharmaceuticals (NASDAQ: ARNA) at Underperform with a $6 price target.
Credit Suisse noted, "We are initiating with an Underperform rating and a $6 target price. ARNA commendably ushered Belviq through FDA; we believe that sales (ARNA has a ~35% royalty) will fall short of the market's lofty expectations."
Arena Pharmaceuticals closed at $9.16 on Wednesday.
Latest Ratings for ARNA
|Sep 2016||FBR Capital||Initiates Coverage on||Outperform|
|Nov 2013||Wallachbeth||Initiates Coverage on||Buy|
|Oct 2013||Cowen & Co.||Initiates Coverage on||Market Perform|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.